Search

Displaying results 2061 - 2070 of 10000 in total
  1. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment

  2. Drug

    Selegiline

    go.drugbank.com/drugs/DB01037
    ApprovedInvestigationalVet approved

    It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. … It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Cetyl alcohol

    go.drugbank.com/drugs/DB09494
    Approved

    Cetyl alcohol is present in a waxy white powder or flake form at room temperature, and is insoluble in water and soluble in alcohols and oils [A32209]. … Discovered by Chevrenl in 1913, cetyl alcohol is one of the oldest known long-chain alcohol [A32209]. It may be contained in cosmetic and personal care products such as shampoos, creams and lotions.

  4. Drug

    Echinacoside

    go.drugbank.com/drugs/DB15488
    Investigational

    [A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592] … Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis,

  5. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. … FDA approved on January 22, 2010.

  6. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    It is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components. … [A263617, A263622] Nogapendekin alfa, in combination with inbakicept, mimics the actions of IL-15, , stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which

    Synonyms: Il-15n72d:il-15rec-su/fc soluble complex i, Fusion protein consisting of il-15n72d and il-15rasu/fc
  7. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636] … [A18696] In 2016, it was granted approval to treat primary biliary cholangitis in combination with [ursodeoxycholic acid], which was previously the mainstay treatment for this condition.

  8. Drug

    AGRO100

    go.drugbank.com/drugs/DB04998
    Investigational

    AGRO100 is an oligonucleotide that functions as an aptamer and binds to nucleolin, a protein found intranuclear in all cells, but uniquely expressed on the surface of tumor cells. … Such binding leads to internalization of the complex, and a strong anti-proliferative response in the tumor cell.

  9. Drug

    Pravastatin

    go.drugbank.com/drugs/DB00175
    ApprovedInvestigational

    Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin].[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. … [L6142] Pravastatin is made through a fermentation process in which [mevastatin] is first obtained.

    Products: Lin-pravastatin
  10. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    [A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. … [A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]